Straumann in the news

Straumann's stock price experienced a slight decrease, with analysts projecting modest profit and dividend increases for the current year.

Straumann's growth is slowing due to regulatory uncertainty in China, impacting patient decisions, despite market share gains in dental implants.

Straumann stock is down 1.1% midday, trading at 82.36 CHF, and is currently below its 52-week high but above its low.

Straumann Holding's stock faces recent negative analyst revisions and market pressure but remains fairly valued with solid growth prospects and moderate sustainability scores.

Straumann's stock fell 0.6% midday, trading below its 52-week high with stable recent revenue and a slight dividend increase forecast.

Straumann grew its 2025 revenue to 2.6 billion CHF with a profit of 478 million CHF, meeting its financial goals.

Straumann's stock price increased by 0.9% to 95.76 CHF with strong trading volume, marking it as a gainer in the SPI index.

Straumann's stock struggles despite recent financial updates, while US competitors gain, partly due to challenges in the Chinese market.

Bernstein keeps an 'Outperform' rating on Straumann after strong Q4 2025 revenue but lowers the price target.

Straumann reported 4.1% revenue growth in 2023, with strong regional variations and cautious outlook for China due to upcoming procurement reforms, aiming for continued growth and margin improvement through 2030.

Straumann Holding AG's financial data, forecasts, and ESG performance are detailed, including several composite ratings based on financial metrics and an excellent MSCI ESG score.

Straumann's stock traded near 81.90 CHF with stable quarterly sales and a 2026 EPS forecast of 3.02 CHF, positioned well below its recent 52-week high.

Bank of America keeps a 'Buy' rating on Straumann despite lowering EPS forecasts, expecting ongoing growth potential.

Straumann Group is enhancing its aligner strategy and managing user consent for various data processing activities to improve its web services and advertising.

Straumann is launching a comprehensive continuing education program in 2026 for dental professionals, covering implantology, digital workflow, and prosthetics, with a focus on practical application and networking.

Renewed US tariff uncertainty following a Supreme Court ruling led to volatility causing slight declines for Straumann and other Swiss stocks amid broader trade and geopolitical concerns.

Straumann grew revenues by 4.1% in 2025, driven by volume, with regional disparities and expects stronger second-half 2026 performance in China amid pricing pressures.

Straumann Group posted strong 2025 growth driven by implant innovation, digital solutions, and strategic orthodontics, while advancing its service-oriented model and expanding production capacity amid leadership transitions.

Straumann's stock declined slightly to 84.10 CHF with stable recent revenue and a forecasted 2026 EPS of 3.06 CHF.

Straumann's stock increased by 1.3% to CHF 84.80 on SIX SX, with analysts expecting a dividend of CHF 1.02 and earnings per share of CHF 3.04 in 2026.